- Home
- BANR vs NVCR Comparison
BANR vs NVCR Comparison
Compare BANR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANR | NVCR |
|---|---|---|
| Founded | 1890 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BANR | NVCR |
|---|---|---|
| Price | $65.68 | $13.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $70.00 | $28.08 |
| AVG Volume (30 Days) | 206.7K | ★ 1.6M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | 15.57 | ★ 21.79 |
| EPS | ★ 1.60 | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $0.73 | $7.72 |
| Revenue Next Year | $5.69 | $6.74 |
| P/E Ratio | $40.52 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $57.05 | $9.82 |
| 52 Week High | $69.83 | $18.92 |
Technical Indicators
Market Signals| Indicator | BANR | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 34.78 |
| Support Level | $62.40 | $12.66 |
| Resistance Level | $67.78 | $14.08 |
| Average True Range (ATR) | 1.38 | 1.02 |
| MACD | -0.02 | -0.43 |
| Stochastic Oscillator | 63.21 | 3.89 |
Price Performance
Historical ComparisonAbout BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.